• Prescribing Information
  • Medical Information
  • Patient Site
  • Order Prevnar 20TM
  • Broad pneumococcal defense1

    Prevnar 20™ helps protect against the 20 Streptococcus pneumoniae serotypes in the vaccine1-4 ​​​​​

    Prevnar 20™ delivers the most serotypes in a pneumococcal conjugate vaccine by adding 7 serotypes to Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])1,5

    Both Prevnar 20™ and Prevnar 13® will only help protect against Streptococcus pneumoniae serotypes in their respective vaccines.1,5


    Developed to help protect against the ongoing threat of pneumococcal disease

    Prevnar 20™ helps protect your patients from 20 prevalent serotypes, which are associated with manifestations of pneumococcal disease, like1,6-9:

    Invasive pneumococcal disease (IPD) Community-acquired pneumonia (CAP)
    Percentage of potential IPD cases covered by vaccine serotypes2*

    There are currently no studies comparing the efficacy of Prevnar 20™ to a 15-valent 
    pneumococcal conjugate vaccine. 
    ​​​​​​​

    IPD=invasive pneumococcal disease.
    ​​​​​​​

    *13 serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 6C (highly related to 6A). 15 serotypes include all 13 serotypes and the additional serotypes 22F and 33F. 
     20 serotypes include all 15 serotypes and the additional serotypes 8, 10A, 11A, 12F, and 15B.

    Percentages based on surveillance data collected by the Centers for Disease Control and Prevention in 2017-2018. 



    References: 1. Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2021. 2. Poehling K, Kobayashi M for the Pneumococcal Work Group. Introduction of the Pneumococcal Work Group. Presented at: Advisory Committee on Immunization Practices; October 28, 2020. Accessed February 5, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/pneumo-01-Poehling-Kobayashi-508.pdf 3. Grant LR, Ramirez J, Self WH, et al. Streptococcus pneumoniae Serotype Distribution and Coverage of Pneumococcal Conjugate Vaccines in Adults Hospitalized with Community-Acquired Pneumonia in the United States. ISPPD. 2020; abstract #879. https://cslide.ctimeetingtech.com/isppd20/attendee/confcal/presentation/list?q=grant  4. Isturiz R, Grant L, Gray S, et al. Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US patients. Clin Infect Dis. Accessed June 16, 2021. [Epub ahead of print]. 5. Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019. 6. Hughes GJ, Wright LB, Chapman KE, Wilson D, Gorton R. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiol Infect. 2016;144(12):2654-2669. 7. Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis. 2009;49(2):e23-e29. 8. Navarro-Torné A, Dias JG, Hruba F, et al. Risk factors for death from invasive pneumococcal disease, Europe, 2010. Emerg Infect Dis. 2015;21(3):417-425. 9. Danis K, Varon E, Lepoutre A, et al. Factors associated with severe nonmeningitis invasive pneumococcal disease in adults in France. Open Forum Infect Dis. 2019;6(12):ofz510. 10. National Foundation for Infectious Diseases. Understanding pneumocccal disease. Accessed November 25, 2020. https://www.nfid.org/wp-content/uploads/2019/09/5-Pneumococcal-Disease-Backgrounder.pdf 11. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806-1812. 12. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. Accessed November 25, 2020. http://hcupnet.ahrq.gov/ 13. Jain S, Self WH, Wunderink RG, et al; for the CDC EPID Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427.

    ​​​​​​​

    Studied across adult populations

    Prevnar 20™ demonstrated immunogenicity in pneumococcal vaccine-naïve and previously vaccinated adults.1

    Evaluate the studies

    ** This is an optional area where footnotes can live.

    Pneumococcal pneumonia can be serious

    Patients can be hospitalized at any time of year, and risks increase with age.10-13

    See the risks

    ** This is an optional area where footnotes can live.

    This site is intended only for US residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    © 2021 Pfizer Inc.

    ​​​​​​​​​​​​All rights reserved.

    Marketed by Pfizer Inc.
    November 2021

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    Marketed by Pfizer Inc.
    © 2021 Pfizer Inc. ​​​​​All rights reserved. November 2021

    Indication

    • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
    • This indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      ​​​​​​​
      • Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20™, Prevnar 13®, or to diphtheria toxoid is a contraindication
      • Safety and immunogenicity data on Prevnar 20™ are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20™
      • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
      • For Prevnar 20™, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults 18 through 59 years of age 
      • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash 

      Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

      Please click for Prevnar 20™ Full Prescribing Information.

      Please click for Prevnar 13® Full Prescribing Information.


      • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older 
      • The indication of Prevnar 20™ for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older

      Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine